ATE504647T1 - Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors - Google Patents

Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors

Info

Publication number
ATE504647T1
ATE504647T1 AT08704115T AT08704115T ATE504647T1 AT E504647 T1 ATE504647 T1 AT E504647T1 AT 08704115 T AT08704115 T AT 08704115T AT 08704115 T AT08704115 T AT 08704115T AT E504647 T1 ATE504647 T1 AT E504647T1
Authority
AT
Austria
Prior art keywords
receptor
mouse
adcc activity
chimeric
human
Prior art date
Application number
AT08704115T
Other languages
English (en)
Inventor
Shigeto Kawai
Original Assignee
Forerunner Pharma Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forerunner Pharma Res Co Ltd filed Critical Forerunner Pharma Res Co Ltd
Application granted granted Critical
Publication of ATE504647T1 publication Critical patent/ATE504647T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT08704115T 2007-01-30 2008-01-30 Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors ATE504647T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007020155 2007-01-30
PCT/JP2008/051333 WO2008093688A1 (ja) 2007-01-30 2008-01-30 キメラFcγレセプター及び該レセプターを用いたADCC活性測定方法

Publications (1)

Publication Number Publication Date
ATE504647T1 true ATE504647T1 (de) 2011-04-15

Family

ID=39673997

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08704115T ATE504647T1 (de) 2007-01-30 2008-01-30 Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors

Country Status (6)

Country Link
US (2) US8946385B2 (de)
EP (1) EP2123754B1 (de)
JP (1) JP5299902B2 (de)
AT (1) ATE504647T1 (de)
DE (1) DE602008006041D1 (de)
WO (1) WO2008093688A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
EP2123754B1 (de) 2007-01-30 2011-04-06 Forerunner Pharma Research Co., Ltd. CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS
US8846870B2 (en) 2008-12-22 2014-09-30 Chugai Seiyaku Kabushiki Kaisha Anti-HS6ST2 antibodies and uses thereof
EP2385114A4 (de) 2008-12-25 2012-08-08 Univ Tokyo Krebsbehandlungsdiagnose mit anti-tm4sf20-antikörper
CA2748990A1 (en) 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
PL2530091T3 (pl) 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
EP2700652B1 (de) 2011-04-18 2018-12-19 The University of Tokyo Diagnose und behandlung von krebs mittels anti-itm2a-antikörpern
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
EP2934532B1 (de) 2012-12-20 2019-10-23 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
CA2935951A1 (en) 2014-01-08 2015-07-16 1Globe Biomedical Co., Ltd. Novel synthetic biology-based adcc technology
RS60398B1 (sr) 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
ES2958720T3 (es) * 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
US11623960B2 (en) 2018-03-20 2023-04-11 National Health Research Institutes Dual-function antibodies targeting VEGFR2 and VEGFR3
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
US20250129136A1 (en) * 2021-12-14 2025-04-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
CZ106299A3 (cs) 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
EP2123754B1 (de) 2007-01-30 2011-04-06 Forerunner Pharma Research Co., Ltd. CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS

Also Published As

Publication number Publication date
EP2123754A1 (de) 2009-11-25
EP2123754A4 (de) 2010-01-27
EP2123754B1 (de) 2011-04-06
JPWO2008093688A1 (ja) 2010-05-20
US20150079610A1 (en) 2015-03-19
DE602008006041D1 (de) 2011-05-19
WO2008093688A1 (ja) 2008-08-07
US8946385B2 (en) 2015-02-03
US20100035280A1 (en) 2010-02-11
US9733245B2 (en) 2017-08-15
JP5299902B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
DE602008006041D1 (de) CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS
Toda et al. Two distinct determinants of ligand specificity in T1R1/T1R3 (the umami taste receptor)
EP2062050A4 (de) Modulation chemosensorischer rezeptoren und damit verbundene liganden
CY1124634T1 (el) Μορια προσδεσης pd-1 και lag-3 και μεθοδοι χρησης αυτων
CY1121796T1 (el) Συνθεσεις μονοσθενεις για δεσμευση cd28 και μεθοδοι χρησης
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
DE602007010420D1 (de) Verfahren zur verwendung des gpr119-rezeptors zur identifizierung von verbindungen zur erhöhung der knochenmasse bei einer person
EP2262911A4 (de) Zusammensetzungen, verfahren und kits mit synthetischen sonden zum nachweis der anwesenheit einer target-nukleinsäure
ATE523777T1 (de) System und verfahren zur bestimmung der analytkonzentration mittels zeitaufgelöster amperometrie
AT505372A3 (de) Verfahren zur quantitativen bestimmung von analyten mit einem testelement sowie testsystem und verwendung desselben
MX2009010620A (es) Marcadores biologicos predictivos de respuesta de artritis reumatoide a antagonistas de celula-b.
MX350957B (es) Moleculas de union especificas para her3 y usos de las mismas.
Martines et al. Single-molecule force spectroscopy of the Aplysia cell adhesion molecule reveals two homophilic bonds
EP2213721A4 (de) Zellmessgefäss, extrazelluläres potentialmessverfahren und chemisches testverfahren
EP1934941A4 (de) Bidirektionales tracking unter verwendung von trajektorien-segmentanalyse
NO20076258L (no) Kimaer human sot-umami og umami-sot smaksreseptorer
ATE509031T1 (de) Verfahren zum erhalten eines konzentrats von von- willebrand-faktor oder eines komplexes von faktor viii/von-willebrand-faktor und verwendung davon
EP2408368A4 (de) Verfahren zur durchgehenden messung einer substratkonzentration
EP2192404A4 (de) Verfahren zur messung einer substratkonzentration und vorrichtung dafür
DK2310043T4 (da) Faktor VIII samt von Willebrand faktor til behandling af koagulationsdefekt in-duceret af trombocythæmmere
AT10236U3 (de) Messanordnung und verfahren zur erfassung von messdaten
EP4174085A4 (de) Antikörper gegen sars-cov-2, verfahren zum nachweis von sars-cov-2 unter verwendung eines antikörpers und kit mit antikörper
EP4421180C0 (de) Zusammensetzungen mit nkg2d, cxcr2 und dap10/dap12 fusionspolypeptiden und verfahren zur verwendung davon
EP3885757C0 (de) Verfahren zur messung des analytentransports über barrieren mit einer röntgenröhre
EP4251644A4 (de) Chimäre rezeptoren und verfahren zur verwendung davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties